⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1588838 | 1.00 | — | — | |
| SCHEMBL4112036 | 1.00 | — | — | |
| SCHEMBL27759726 | 0.82 | LMNA (0.38) | — | |
| SCHEMBL172671 | 0.82 | ALDH1A1 (0.37) | — | |
| SCHEMBL24467474 | 0.79 | — | — | |
| SCHEMBL26457823 | 0.79 | TSHR (0.38) | — | |
| SCHEMBL761643 | 0.78 | — | — | |
| SCHEMBL24298268 | 0.78 | — | — | |
| SCHEMBL18569551 | 0.77 | LMNA (0.41) | — | |
| SCHEMBL13996920 | 0.76 | TSHR (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023196429-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-12 | — | — | WO | disclosed |
| CN-116601158-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-08-15 | — | — | CN | disclosed |
| EP-3929185-A1 | NITROGEN-CONTAINING FUSED CYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2021-12-29 | — | — | EP | disclosed |
| EP-3510024-B1 | PYRIDYL SUBSTITUTED INDOLE COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3901154-A1 | PURINE DERIVATIVES AS DRUGS FOR THE TREATMENT OF NEONATAL HYPOXIA-ISCHEMIA BRAIN INJURY AND RELATED DISEASES | Commissariat à l'énergie atomique et aux énergies alternatives (FR) | 2021-10-27 | — | — | EP | disclosed |
| WO-2021086726-A1 | IMPROVED METHODS, KITS, COMPOSITIONS AND DOSING REGIMENS FOR THE USE OF HETEROCYCLIC INHIBITORS OF ERK1 AND ERK2 | Asan BioSciences, LLC (US) | 2021-05-06 | — | — | WO | disclosed |
| WO-2018049089-A1 | PYRIDYL SUBSTITUTED INDOLE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-15 | — | — | WO | disclosed |
| WO-2014012074-A2 | NO-RELEASING NONOATE (NITROGEN-BOUND) SULFONAMIDE-LINKED-COXIB ANTI-CANCER AGENTS | Euclises Pharmaceuticals, Inc. (US) | 2014-01-16 | — | — | WO | disclosed |
| US-8044072-B2 | Pyrrole derivatives, preparation thereof and therapeutic use thereof | SANOFI AVENTIS (FR) | 2011-10-25 | — | — | US | disclosed |
| US-8044072-B2 | Pyrrole derivatives, preparation thereof and therapeutic use thereof | SANOFI AVENTIS (FR) | 2011-10-25 | — | — | US | disclosed |
| US-20090281116-A1 | PYRROLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-7459460-B2 | Trisubstituted heteroaromatic compounds as calcium sensing receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-12-02 | — | — | US | disclosed |
| US-20080275046-A1 | Compounds Comprising an Oxazole or Thiazole Moiety, Processes for Making Them, and Their Uses | UCB PHARMA, S.A. (BE) | 2008-11-06 | — | — | US | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| WO-2008082490-A2 | NOVEL JNK INHIBITORS | SCHERING CORPORATION (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008068423-A2 | P<0}{0PYRROL DERIVATIVES, PREPARATION AND USE OF THE SAME IN THERAPY<0} | SANOFI-AVENTIS (FR) | 2008-06-12 | — | — | WO | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20070129394-A1 | Rapamycin peptides conjugates: synthesis and uses thereof | QUEST PHARMATECH, INC. (CA) | 2007-06-07 | — | — | US | disclosed |
| EP-1675862-A1 | NEW 2-SUBSTITUTED, 4-AMINO-THIAZOLO 4,5-D PYRIMIDINES, USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS, ESP. CX3CR1 | AstraZeneca AB (SE) | 2006-07-05 | — | — | EP | disclosed |
| WO-2005033115-A1 | NEW 2-SUBSTITUTED, 4-AMINO-THIAZOLO[4,5-D] PYRIMIDINES, USEFUL AS CHEMOKINE RECEPTOR ANTAGONISTS, ESP. CX3CR1 | ASTRAZENECA AB (SE) | 2005-04-14 | — | — | WO | disclosed |